Nevirapine
| 證據等級: L5 | 預測適應症: 3 個 |
目錄
Nevirapine: From HIV-1 Infection to Feline Acquired Immunodeficiency Syndrome
One-Sentence Summary
Nevirapine is an approved HIV-1 non-nucleoside reverse transcriptase inhibitor (NNRTI). The TxGNN model predicts it may be effective for Feline Acquired Immunodeficiency Syndrome (FIV infection in cats), but this direction is currently supported by only 1 publication and no clinical trials, and that single study raises caution rather than confirming efficacy.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | HIV-1 infection (nevirapine is referenced in the evidence pack as an "approved HIV-1 non-nucleoside reverse transcriptase inhibitor"; a formal indication text/MOA record is not yet on file) |
| Predicted New Indication | Feline Acquired Immunodeficiency Syndrome (FIV) |
| TxGNN Prediction Score | 99.85% |
| Evidence Level | L4 |
| Finland Market Status | Not marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in this evidence pack (flagged as a High-severity data gap). Based on the information that is available, nevirapine is known to act as an NNRTI that binds the hydrophobic allosteric pocket of HIV-1 reverse transcriptase (RT), a mechanism referenced elsewhere in this same evidence pack.
Feline immunodeficiency virus (FIV) causes an AIDS-like syndrome in cats and, like HIV-1, depends on a reverse transcriptase for replication — the superficial rationale for testing HIV-1 NNRTIs against it. However, the sole supporting publication (PMID 38031646) is a structural/biochemical comparison of NNRTIs against feline vs. human RT, and this type of study is typically conducted precisely because the two RTs differ significantly in structure. The evidence therefore points toward limited or unpredictable cross-species inhibition, not demonstrated efficacy.
Taken together, the mechanistic plausibility is weak: the link is a shared drug class/target family rather than confirmed cross-species activity, and FIV is a veterinary (non-human) indication that sits outside the typical human drug-repurposing development pathway.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 38031646 | 2023 | Structural/biochemical comparison study | Journal of Veterinary Science | Compared nevirapine, efavirenz, and rilpivirine biochemically/structurally against feline vs. human RT to assess NNRTI potential for treating FIV-infected cats; no effective FIV treatment currently exists |
Finland Market Information
Nevirapine is currently not marketed in Finland, and no marketing authorizations are on record.
Safety Considerations
Please refer to the package insert for safety information. (TFDA package insert data was queried but is currently a Blocking-severity data gap in this evidence pack, preventing a full safety review.)
Conclusion and Next Steps
Decision: Hold
Rationale: Evidence for this indication rests on a single preclinical structural/biochemical comparison study with no clinical trials, and that study itself suggests cross-species RT inhibition may be limited rather than confirming therapeutic benefit. The candidate indication is also a veterinary disease (feline FIV), which falls outside standard human drug-repurposing evaluation.
To proceed, the following is needed:
- TFDA package insert data (warnings/contraindications) — currently a Blocking gap preventing S1 safety evaluation
- Detailed mechanism of action (MOA) data for nevirapine — currently a High-severity gap
- In vivo/in vitro efficacy data specifically demonstrating antiviral activity against FIV (not just structural RT comparison)
- If a human-relevant repurposing signal is desired, note that rank 2 in this evidence pack (simian immunodeficiency virus infection, L3/S1, 17 supporting publications) has a stronger and more direct mechanistic basis, though it also concerns a non-human model rather than a human indication
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.